

**Table S1. Study Design Characteristics.**

	Melanoma (N=147)	cSCC (N=59)	BCC (N=94)
Date range	1980 - 2018	1941 - 2017	1941 - 2017
Study type (%)			
Retrospective chart review	65 (44.2)	14 (23.7)	12 (12.8)
Experimental design	40 (27.2)	16 (27.1)	53 (56.4)
Systemic review or meta-analysis	9 (6.1)	6 (10.2)	9 (9.6)
Literature review	7 (4.8)	6 (10.2)	3 (3.2)
Society guidelines	5 (3.4)	2 (3.4)	4 (4.3)
Prospective observational cohort study	3 (2.0)	7 (11.9)	8 (8.5)
Pooled data	3 (2.0)	0 (0.0)	0 (0.0)
Case report n<5	1 (0.7)	5 (8.5)	3 (3.2)
Case series n>5	1 (0.7)	2 (3.4)	1 (1.1)
Book chapter	1 (0.7)	0 (0.0)	0 (0.0)
Commentary	0 (0.0)	0 (0.0)	0 (0.0)
Other	12 (8.2)	1 (1.7)	1 (1.1)
<b>Experimental randomization (%) †</b>	<b>40</b>	<b>16</b>	<b>53</b>
Randomized	22 (55.0)	11 (68.8)	41 (77.4)
Non-randomized	18 (45.0)	5 (31.2)	12 (22.6)
<b>Clinical trials (%) †</b>	<b>16</b>	<b>4</b>	<b>11</b>
Phase 1	3 (18.8)	0 (0.0)	0 (0.0)
Phase 1/2	1 (6.3)	0 (0.0)	0 (0.0)
Phase 2	2 (12.5)	3 (75.0)	5 (45.5)
Phase 2/3	0 (0.0)	0 (0.0)	2 (18.2)
Phase 3	10 (62.5)	1 (25.0)	4 (36.4)
Phase 4	0 (0.0)	0 (0.0)	0 (0.0)
<b>Study location (%) ††</b>	<b>99</b>	<b>44</b>	<b>63</b>
North America	61 (61.6)	16 (36.4)	22 (34.9)
South America	4 (4.0)	2 (4.5)	1 (1.6)
Europe	37 (37.4)	18 (40.9)	34 (54.0)
Australia and Oceania	17 (17.2)	6 (13.6)	14 (22.2)
Asia	1 (1.0)	2 (4.5)	2 (3.2)
Africa	4 (4.0)	0 (0.0)	0 (0.0)

† Percentages are based on the total N of the subgroup, displayed in the cells to the right. †† percentages may add up to over 100% because some studies had multiple study locations. *Abbreviations:* BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.